Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, announced terms for its Nasdaq IPO on Tuesday.
The London, United Kingdom-based company plans to raise $16 million by offering 1.575 million ADSs at $10.25, the as-converted price of its shares on London's AIM (symbol: TILS). At that price, Tiziana Life Sciences would command a fully diluted market value of $212 million.
The pre-revenue company was founded in 1998 and plans to list on the Nasdaq under the symbol TLSA. Laidlaw & Company (UK) is the sole bookrunner on the deal. Deal timing was not announced.
